Journal of Pathology and Translational Medicine

Case Study

Squamous Cell Carcinoma of the Extrahepatic Common Hepatic Duct: Myunghee Kang, Na Rae Kim, Dong Hae Chung, Hyun Yee Cho, Yeon Ho Park; J Pathol Transl Med. 2019;53(2):112-118. Published online October 1, 2018; DOI: https://doi.org/10.4132/jptm.2018.09.03

6,853 View
170 Download
8 Web of Science
9 Crossref

We report a rare case of hilar squamous cell carcinoma. A 62-year-old Korean woman complaining of nausea was referred to our hospital. Her biliary computed tomography revealed a 28 mm-sized protruding solid mass in the proximal common bile duct. The patient underwent left hemihepatectomy with S1 segmentectomy and segmental excision of the common bile duct. Microscopically, the tumor was a moderately differentiated squamous cell carcinoma of the extrahepatic bile duct, without any component of adenocarcinoma or metaplastic portion in the biliary epithelium. Immunohistochemically, the tumor was positive for cytokeratin (CK) 5/6, CK19, p40, and p63. Squamous cell carcinoma of the extrahepatic bile duct is rare. To date, only 24 cases of biliary squamous cell carcinomas have been reported. Here, we provide a clinicopathologic review of previously reported extrahepatic bile duct squamous cell carcinomas.

Citations

Citations to this article as recorded by

Cholangiocarcinoma With Liver Metastasis in Squamous Cell Carcinoma Type: A Case Report
Jane Chiang
Journal of Diagnostic Medical Sonography.2024; 40(6): 609. CrossRef
A Rare Case of Squamous Cell Carcinoma of the Bile Duct
Julianna Tantum, Rachael Schneider, Stefanie Gallagher, Kyley Leroy, Jared Lander, Patricia Wong
ACG Case Reports Journal.2023; 10(8): e01119. CrossRef
Metastatic Anal Squamous Cell Carcinoma Presenting as an Indeterminate Biliary Stricture Diagnosed By Cholangioscopy
Ritu Nahar, Ian Holmes, Jeffrey Baliff, Austin Chiang, Thomas Kowalski
ACG Case Reports Journal.2022; 9(6): e00785. CrossRef
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017
Milind Javle, Sunyoung Lee, Nilofer S Azad, Mitesh J Borad, Robin Kate Kelley, Smitha Sivaraman, Anna Teschemaker, Ishveen Chopra, Nora Janjan, Shreekant Parasuraman, Tanios S Bekaii-Saab
The Oncologist.2022; 27(10): 874. CrossRef
PRIMARY SQUAMOUS CELL CARCINOMA OF THE COMMON BILE DUCT WITH LIVER METASTASES
Dhouha BACHA, Mohamed HAJRI, Wael FERJAOUI, Ghofrane TALBI, Lasaad GHARBI, Mohamed Taher KHALFALLAH, Sana ben SLAMA, Ahlem LAHMAR
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2021;[Epub] CrossRef
S1510 A Rare Case of Squamous Cell Carcinoma of the Bile Duct
Stefanie Gallagher, Kyley Leroy, Julianna Tantum, Babak Etemad
American Journal of Gastroenterology.2021; 116(1): S688. CrossRef
Heparin

Reactions Weekly.2019; 1752(1): 184. CrossRef
Carcinoma primario de células escamosas del conducto hepático común: a propósito de un caso
Ana Delgado Maroto, Andrés Barrientos Delgado, Marta Lázaro Sáez, Samia Hallouch Toutouh, Enrique Práxedes González
Gastroenterología y Hepatología.2019; 42(7): 436. CrossRef
Primary squamous cell carcinoma of the extrahepatic bile duct: A case report
Ana Delgado Maroto, Andrés Barrientos Delgado, Marta Lázaro Sáez, Samia Hallouch Toutouh, Enrique Práxedes González
Gastroenterología y Hepatología (English Edition).2019; 42(7): 436. CrossRef

Original Articles

Myoferlin Expression and Its Correlation with FIGO Histologic Grading in Early-Stage Endometrioid Carcinoma: Min Hye Kim, Dae Hyun Song, Gyung Hyuck Ko, Jeong Hee Lee, Dong Chul Kim, Jung Wook Yang, Hyang Im Lee, Hyo Jung An, Jong Sil Lee; J Pathol Transl Med. 2018;52(2):93-97. Published online March 14, 2018; DOI: https://doi.org/10.4132/jptm.2017.11.29

6,271 View
117 Download
11 Web of Science
9 Crossref

Abstract PDF

Background
For endometrioid carcinoma patients, International Federation of Gynecologists and Obstetricians (FIGO) histologic grading is very important for identifying the appropriate treatment method. However, the interobserver discrepancy with this three-tiered grading system is a serious potential problem. In this study, we used immunohistochemistry to analyze the relationship between FIGO histologic grading score and myoferlin expression.
Methods
We studied the endometrioid carcinoma tissues of 60 patients from Gyeongsang National University Hospital between January 2002 and December 2009. Immunohistochemical analysis of myoferlin was performed on tissue microarray blocks from surgical specimens.
Results
Myoferlin expression was observed in 58 of 60 patients. Moderate and strong myoferlin expression was observed in low-grade endometrioid carcinoma, while there was a tendency toward loss of myoferlin expression in high-grade endometrioid carcinoma (p<.001).
Conclusions
Our study revealed that myoferlin loss is significantly correlated with high FIGO grade of endometrioid carcinoma.

Citations

Citations to this article as recorded by

Myoferlin: A Potential Marker of Response to Radiation Therapy and Survival in Locally Advanced Rectal Cancer
Hayley Fowler, Rachael E. Clifford, David Bowden, Paul A. Sutton, Naren Govindarajah, Matthew Fok, Mark Glenn, Michael Wall, Carlos Rubbi, Simon J.A. Buczacki, Amit Mandal, Hayley Francies, Jonathan Hughes, Jason L. Parsons, Dale Vimalachandran
International Journal of Radiation Oncology*Biology*Physics.2024; 120(4): 1111. CrossRef
Neoexpression of JUNO in Oral Tumors Is Accompanied with the Complete Suppression of Four Other Genes and Suggests the Application of New Biomarker Tools
Dominik Kraus, Simone Weider, Rainer Probstmeier, Jochen Winter
Journal of Personalized Medicine.2022; 12(3): 494. CrossRef
Correlation between myoferlin expression and lymph node metastasis in papillary thyroid carcinoma
Ji Min Na, Dong Chul Kim, Dae Hyun Song, Hyo Jung An, Hyun Min Koh, Jeong-Hee Lee, Jong Sil Lee, Jung Wook Yang, Min Hye Kim
Journal of Pathology and Translational Medicine.2022; 56(4): 199. CrossRef
PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis
Tao Qian, Chengmin Liu, Yanyan Ding, Chen Guo, Renwei Cai, Xiaoxia Wang, Rong Wang, Kuo Zhang, Li Zhou, Yi Deng, Chuanyue Wu, Ying Sun
Oncogene.2020; 39(10): 2069. CrossRef
Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis
Gilles Rademaker, Brunella Costanza, Justine Bellier, Michael Herfs, Raphaël Peiffer, Ferman Agirman, Naïma Maloujahmoum, Yvette Habraken, Philippe Delvenne, Akeila Bellahcène, Vincent Castronovo, Olivier Peulen
Oncogenesis.2019;[Epub] CrossRef
Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression
Minsun Jung, Cheol Lee, Jeong Hwan Park, Kyung Chul Moon
Urologic Oncology: Seminars and Original Investigations.2019; 37(11): 812.e9. CrossRef
Ferlin Overview: From Membrane to Cancer Biology
Olivier Peulen, Gilles Rademaker, Sandy Anania, Andrei Turtoi, Akeila Bellahcène, Vincent Castronovo
Cells.2019; 8(9): 954. CrossRef
Myoferlin, a multifunctional protein in normal cells, has novel and key roles in various cancers
Wei Zhu, Bolun Zhou, Chenxuan Zhao, Zhengqing Ba, Hongjuan Xu, Xuejun Yan, Weidong Liu, Bin Zhu, Lei Wang, Caiping Ren
Journal of Cellular and Molecular Medicine.2019; 23(11): 7180. CrossRef
Myoferlin, a Membrane Protein with Emerging Oncogenic Roles
Yimin Dong, Honglei Kang, Huiyong Liu, Jia Wang, Qian Guo, Chao Song, Yunlong Sun, Ya Zhang, Honghua Zhang, Zheng Zhang, Hanfeng Guan, Zhong Fang, Feng Li
BioMed Research International.2019; 2019: 1. CrossRef

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period: Misun Choi, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Soo Youn Cho, Eun Yoon Cho; J Pathol Transl Med. 2017;51(1):69-78. Published online December 25, 2016; DOI: https://doi.org/10.4132/jptm.2016.10.05

10,615 View
266 Download
21 Web of Science
20 Crossref

Abstract PDF

Background
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) has been associated with favorable clinical outcome in breast cancer patients. However, the possibility that the prognostic significance of pCR differs among various definitions has not been established. Methods: We retrospectively evaluated the pathologic response after NAC in 353 breast cancer patients and compared the prognoses after applying the following different definitions of pCR: ypT0/is, ypT0, ypT0/is ypN0, and ypT0 ypN0. Results: pCR was significantly associated with improved distant disease-free survival (DDFS) regardless of the definition (ypT0/is, p = .002; ypT0, p = .008; ypT0/is ypN0, p < .001; ypT0 ypN0, p = .003). Presence of tumor deposits of any size in the lymph nodes (LNs; ypN ≥ 0(i+)) was associated with worse DDFS (ypT0 ypN0 vs ypT0 ypN ≥ 0(i+), p = .036 and ypT0/is ypN0 vs ypT0/is ypN ≥ 0(i+), p = .015), and presence of isolated tumor cells was associated with decreased overall survival (OS; ypT0/is ypN0 vs ypT0/is ypN0(i+), p = .013). Residual ductal carcinoma in situ regardless of LN status showed no significant difference in DDFS or OS (DDFS: ypT0 vs ypTis, p = .373 and ypT0 ypN0 vs ypTis ypN0, p = .462; OS: ypT0 vs ypTis, p = .441 and ypT0 ypN0 vs ypTis ypN0, p = .758). In subsequent analysis using ypT0/is ypN0, pCR was associated with improved DDFS and OS in triple-negative tumors (p < .001 and p = .003, respectively). Conclusions: Based on our study results, the prognosis and rate of pCR differ according to the definition of pCR and ypT0/is ypN0 might be considered a more preferable definition of pCR.

Citations

Citations to this article as recorded by

Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status
Eunju Shin, Tae-Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee
Discover Oncology.2024;[Epub] CrossRef
Pathology after neoadjuvant treatment – How to assess residual disease
Giuseppe Viale, Nicola Fusco
The Breast.2022; 62: S25. CrossRef
Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC)
Nicola Fusco, Antonio Rizzo, Leopoldo Costarelli, Alfredo Santinelli, Bruna Cerbelli, Cristian Scatena, Ettore Macrì, Francesca Pietribiasi, Giulia d’Amati, Anna Sapino, Isabella Castellano
Pathologica.2022; 114(2): 104. CrossRef
Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Matthew G. Davey, Ferdia Browne, Nicola Miller, Aoife J. Lowery, Michael J. Kerin
BJS Open.2022;[Epub] CrossRef
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
Lisi M. Dredze, Michael Friger, Samuel Ariad, Michael Koretz, Bertha Delgado, Ruthy Shaco-Levy, Margarita Tokar, Michael Bayme, Ravit Agassi, Maia Rosenthal, Victor Dyomin, Olga Belochitski, Shai Libson, Tamar Mizrahi, David B. Geffen
Breast Cancer Research and Treatment.2022; 193(3): 597. CrossRef
“No Ink on Tumor” in Breast-Conserving Surgery after Neoadjuvant Chemotherapy
Giulia Atzori, Marco Gipponi, Chiara Cornacchia, Raquel Diaz, Marco Sparavigna, Maurizio Gallo, Tommaso Ruelle, Federica Murelli, Simonetta Franchelli, Francesca Depaoli, Daniele Friedman, Piero Fregatti
Journal of Personalized Medicine.2022; 12(7): 1031. CrossRef
Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer
Carmen Herrero Vicent, Xavier Tudela, Paula Moreno Ruiz, Víctor Pedralva, Ana Jiménez Pastor, Daniel Ahicart, Silvia Rubio Novella, Isabel Meneu, Ángela Montes Albuixech, Miguel Ángel Santamaria, María Fonfria, Almudena Fuster-Matanzo, Santiago Olmos Antó
Cancers.2022; 14(14): 3508. CrossRef
Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction
Meredith A. Jones, Warid Islam, Rozwat Faiz, Xuxin Chen, Bin Zheng
Frontiers in Oncology.2022;[Epub] CrossRef
Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy
Ina Jani, Ricardo R Lastra, Katherine S Brito, Chuanhong Liao, Isabel Lazo, Nita Karnik Lee, S Diane Yamada, Katherine C Kurnit
International Journal of Gynecologic Cancer.2021; 31(6): 852. CrossRef
Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
Yu Zhang, Di Wu, Bo Zhao, Xue-Liang Tian, Tian-Cheng Yao, Feng Li, Wei-Fang Liu, Ai-Ping Shi
World Journal of Clinical Cases.2021; 9(4): 919. CrossRef
Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis
Hui Liu, Liqiong Lv, Hui Gao, Ming Cheng, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef
Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival
K. Wimmer, M. Bolliger, Z. Bago-Horvath, G. Steger, D. Kauer-Dorner, R. Helfgott, C. Gruber, F. Moinfar, M. Mittlböck, F. Fitzal
Annals of Surgical Oncology.2020; 27(5): 1700. CrossRef
Predictive factors for omitting lymphadenectomy in patients with node‐positive breast cancer treated with neo‐adjuvant systemic therapy
Sergi Fernandez‐Gonzalez, Catalina Falo, Maria J. Pla, Paula Verdaguer, Diana Nuñez, Anna Guma, Teresa Soler, Andrea Vethencourt, Silvia Vázquez, Maria Eulalia Fernandez‐Montoli, Miriam Campos, Sonia Pernas, Miguel Gil, Jordi Ponce, Amparo Garcia‐Tejedor
The Breast Journal.2020; 26(5): 888. CrossRef
Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?
Qian Wang, Jingjing Zhao, Xiaowei Han, Puchun Er, Xiangying Meng, Jinyan Shi, Huiru Sun, Jingyang Zhu, Li Zhu, Shikai Wu, Wencheng Zhang, Bing Sun
Frontiers in Oncology.2020;[Epub] CrossRef
Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer
Rajat Bajaj, Rupal Tripathi, T. S. Sridhar, Aruna Korlimarla, Kumardeep Dutta Choudhury, Moushumi Suryavanshi, Anurag Mehta, Dinesh Chandra Doval, Elda Tagliabue
PLOS ONE.2020; 15(11): e0242190. CrossRef
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Min Huang, Joyce O'Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortés, Scott D. Ramsey, Andrew Briggs, Peter Hu, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, Peter A. Fasch
Cancer Research.2020; 80(24): 5427. CrossRef
Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response
G Santamaría, X Bargalló, S Ganau, I Alonso, M Muñoz, M Mollà, PL Fernández, A Prat
European Journal of Radiology.2019; 117: 132. CrossRef
Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy
Reshu Agarwal, Arun Philip, Keechilat Pavithran, Anupama Rajanbabu, Gaurav Goel, DK Vijaykumar
Indian Journal of Cancer.2019; 56(3): 228. CrossRef
Application of neoadjuvant chemotherapy in occult breast cancer
Haisong Yang, Ling Li, Mengmeng Zhang, Shiyong Zhang, Shu Xu, Xiaoxia Ma
Medicine.2017; 96(40): e8200. CrossRef
Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer
Kijong Yi, Kyueng-Whan Min, Young Chan Wi, Yeseul Kim, Su-Jin Shin, Min Sung Chung, Kiseok Jang, Seung Sam Paik
Journal of Breast Cancer.2017; 20(4): 361. CrossRef

Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers: Jung Ho Kim, Jeong Mo Bae, Hyeon Jeong Oh, Hye Seung Lee, Gyeong Hoon Kang; J Pathol Transl Med. 2015;49(2):118-128. Published online March 12, 2015; DOI: https://doi.org/10.4132/jptm.2015.02.05

10,909 View
119 Download
19 Web of Science
16 Crossref

Abstract PDF

Background
Although there are controversies regarding the benefit of fluoropyrimidine-based adjuvant chemotherapy in patients with microsatellite instability–high (MSI-H) colorectal cancer (CRC), the pathologic features affecting postchemotherapeutic prognosis in these patients have not been fully identified yet. Methods: A total of 26 histopathologic and immunohistochemical factors were comprehensively evaluated in 125 stage II or III MSI-H CRC patients who underwent curative resection followed by fluoropyrimidine-based adjuvant chemotherapy. We statistically analyzed the associations of these factors with disease-free survival (DFS). Results: Using a Kaplan- Meier analysis with log-rank test, we determined that ulceroinfiltrative gross type (p=.003), pT4 (p<.001), pN2 (p=.002), perineural invasion (p=.001), absence of peritumoral lymphoid reaction (p=.041), signet ring cell component (p=.006), and cribriform comedo component (p=.004) were significantly associated with worse DFS in patients receiving oxaliplatin-based adjuvant chemotherapy (n=45). By contrast, pT4 (p<.001) and tumor budding-positivity (p=.032) were significant predictors of poor survival in patients receiving non-oxaliplatin–based adjuvant chemotherapy (n=80). In Cox proportional hazards regression model-based univariate and multivariate analyses, pT category (pT1-3 vs pT4) was the only significant prognostic factor in patients receiving non-oxaliplatin–based adjuvant chemotherapy, whereas pT category, signet ring cell histology and cribriform comedo histology remained independent prognostic factors in patients receiving oxaliplatin-based adjuvant chemotherapy. Conclusions: pT4 status is the most significant pathologic determinant of poor outcome after fluoropyrimidine-based adjuvant chemotherapy in patients with stage II/III MSI-H CRC.

Citations

Citations to this article as recorded by

Clinicopathological features and evaluation of microsatellite stability of colorectal carcinoma with cribriform comedo pattern
Tuğba Günler, Pinar Karabağli, Hicret Tiyek, Özge Keskin, Muslu K. Körez
Indian Journal of Pathology and Microbiology.2024; 67(2): 275. CrossRef
Evaluation of D-Mannoheptulose and Doxorubicin as Potential Therapeutic Agents for Breast Cancer by Targeting Glycolysis and Inducing Apoptosis
Ahmed Ghdhban Al-Ziaydi
Indian Journal of Clinical Biochemistry.2024;[Epub] CrossRef
Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability
Alexander S Taylor, Natalia Liu, Jiayun M Fang, Nicole Panarelli, Lili Zhao, Jerome Cheng, Purva Gopal, Suntrea Hammer, Jing Sun, Henry Appelman, Maria Westerhoff
Journal of Clinical Pathology.2022; 75(7): 483. CrossRef
HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability
Gaelle Tachon, Arnaud Chong-Si-Tsaon, Thierry Lecomte, Audelaure Junca, Éric Frouin, Elodie Miquelestorena-Standley, Julie Godet, Camille Evrard, Violaine Randrian, Romain Chautard, Marie-Luce Auriault, Valérie Moulin, Serge Guyetant, Gaelle Fromont, Luci
Frontiers in Genetics.2022;[Epub] CrossRef
Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma
Guang-Qian Xiao, Elise Nguyen, Pamela D. Unger, Andy E. Sherrod
Experimental and Molecular Pathology.2020; 114: 104400. CrossRef
Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System
Jong Woo Lee, Jae Hoon Lee, Yejong Park, Woohyung Lee, Jaewoo Kwon, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim
Cancer Research and Treatment.2020; 52(3): 886. CrossRef
Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system
Jae Seung Kang, Seungyeoun Lee, Donghee Son, Youngmin Han, Kyung Bun Lee, Jae Ri Kim, Wooil Kwon, Sun‐Whe Kim, Jin‐Young Jang
Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(2): 124. CrossRef
Invasion Depth Measured in Millimeters is a Predictor of Survival in Patients with Distal Bile Duct Cancer: Decision Tree Approach
Kyueng‐Whan Min, Dong‐Hoon Kim, Byoung Kwan Son, Eun‐Kyung Kim, Sang Bong Ahn, Seong Hwan Kim, Yun Ju Jo, Young Sook Park, Jinwon Seo, Young Ha Oh, Sukjoong Oh, Ho Young Kim, Mi Jung Kwon, Soo Kee Min, Hye‐Rim Park, Ji‐Young Choe, Jang Yong Jeon, Hong Il
World Journal of Surgery.2017; 41(1): 232. CrossRef
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-TypeBRAF-Expressing Cancer Independent of the Microsatellite Instability Status
Min Hye Jang, Sehun Kim, Dae Yong Hwang, Wook Youn Kim, So Dug Lim, Wan Seop Kim, Tea Sook Hwang, Hye Seung Han
Journal of Korean Medical Science.2017; 32(1): 38. CrossRef
Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma
Hye Eun Park, Jung Ho Kim, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang
Virchows Archiv.2017; 471(3): 329. CrossRef
Dominant high expression of wild‐type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole‐section immunohistochemical analysis
Hyeon Jeong Oh, Jung Ho Kim, Tae Hun Lee, Hye Eun Park, Jeong Mo Bae, Hye Seung Lee, Gyeong Hoon Kang
APMIS.2017; 125(12): 1076. CrossRef
TNM Staging of Colorectal Cancer Should be Reconsidered According to Weighting of the T Stage
Jun Li, Cheng-Hao Yi, Ye-Ting Hu, Jin-Song Li, Ying Yuan, Su-Zhan Zhang, Shu Zheng, Ke-Feng Ding
Medicine.2016; 95(6): e2711. CrossRef
Molecular genetics of colorectal cancer
James Church
Seminars in Colon and Rectal Surgery.2016; 27(4): 172. CrossRef
Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers
Jung Ho Kim, Hye Eun Park, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang
British Journal of Cancer.2016; 115(4): 490. CrossRef
Distinct features betweenMLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway
Jung Ho Kim, Jeong Mo Bae, Nam-Yun Cho, Gyeong Hoon Kang
Oncotarget.2016; 7(12): 14095. CrossRef
Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy
Lu-Ning Zhang, Wei-Wei Xiao, Shao-Yan Xi, Pu-Yun OuYang, Kai-Yun You, Zhi-Fan Zeng, Pei-Rong Ding, Hui-Zhong Zhang, Zhi-Zhong Pan, Rui-Hua Xu, Yuan-Hong Gao
Oncotarget.2016; 7(5): 6335. CrossRef

Case Report

Maxillo-facial Extraskeletal Myxoid Chondrosarcoma: A Case Report and Discussion.: Ratnadeep Ganguly, Abhishek Mukherjee; Korean J Pathol. 2011;45(6):639-643.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.6.639

3,166 View
24 Download
2 Crossref

Abstract PDF

In this report, we share our experience of a case of maxillo-facial extraskeletal myxoid chondrosarcoma, a very rare location for this neoplasm. In addition, a literature review is provided. The patient, a 61-year-old male, had a maxillary mass encroaching on the nasal cavity. After debulking, the tumor recurred, attaining its pre-surgical proportion in two months. The patient improved clinically with radiation and remained stable for about one year. However, he ultimately developed metastases in his lung which were treated with palliative chemotherapy with a good outcome lasting three months. We could find only eight reported cases of this tumor in the head region of which two are in the maxilla; hence, ruling out other primary sites is mandatory for a patient presenting with a primary head and neck mass. Surgical removal may be complicated because of the location. A combination of surgery and radiation is the management of choice, with palliative chemotherapy in metastasis.

Citations

Citations to this article as recorded by

Extraskeletal Myxoid Chondrosarcoma of Floor of Mouth—A Rare Case Report and Review of Literature
Surendra K Dabas, Nandini N Menon, Reetesh Ranjan, Bikas Gurung, Sukirti Tiwari, Bharat Bhushan Bassan, Himanshu Shukla, Sunil Pasricha, Ajit Sinha, Rahul Kapoor, Vinay Kumar Verma, Devesh Verma, Saurabh Arora, Ashwani Sharma, Sourabh Mukharjee, Rishu Sin
Indian Journal of Otolaryngology and Head & Neck Surgery.2024; 76(1): 1290. CrossRef
Intracranial Metastasis of Extracranial Chondrosarcoma: Systematic Review With Illustrative Case
Charles E. Mackel, Harry Rosenberg, Hemant Varma, Erik J. Uhlmann, Rafael A. Vega, Ron L. Alterman
Brain Tumor Research and Treatment.2023; 11(2): 103. CrossRef

Original Articles

ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC.: Han Suk Ryu, Xianhua Xu, Hyojin Kim, Jong Suk Lee, Sanghoon Jheon, Jin Haeng Chung; Korean J Pathol. 2011;45(1):45-52.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.1.45

2,708 View
18 Download

Abstract PDF: BACKGROUND
The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy.
METHODS
The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146).
RESULTS
Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001).
CONCLUSIONS
These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.

Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer.: Jinyoung Yoo, Byoung Yong Shim, Chang Young Yoo, Seok Jin Kang, Kyo Young Lee; Korean J Pathol. 2009;43(5):435-440.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.5.435

3,414 View
37 Download
1 Crossref

Abstract PDF

BACKGROUND
Taxane-platinum combinations are often used as first-line treatments for patients with advanced non-small cell lung cancer (NSCLC). Response to chemotherapy for these patients is still poor. The aim of our study was to investigate, for this disease, whether KRAS and Tau proteins affect responses to taxane-platinum combinations.
METHODS
Expression of KRAS and Tau was examined immunohistochemically in 71 tumor samples obtained from patients with stage IIIB or IV NSCLC prior to combination therapy. Expression was correlated with tumor responses.
RESULTS
The response rate was 55% (39 of 71). KRAS and Tau were expressed in seven (10%) and 31 (44%) patients, respectively. All seven KRAS-positive patients were non-responders (p=0.014). Among Tau-positive patients, 35% (11 of 31) responded to therapy, whereas a partial response was observed in 70% (28 of 40) of Tau-negatives (p=0.045). Two were positive for both, and they were non-responders. In patients negative for both, the response rate was 71% (25 of 35) (p=0.012).
CONCLUSIONS
Expression of KRAS and Tau are significantly correlated with poor responses to this combination therapy in advanced NSCLC patients, and may be a useful marker for chemoresistance.

Citations

Citations to this article as recorded by

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer
Stéphanie Papin, Paolo Paganetti
Brain Sciences.2020; 10(11): 862. CrossRef

A High Thymidylate Synthase Expression is Related to Better Outcome for Advanced Gastric Cancer Patients Treated with 5-FU Chemotherapy after Curative Resection.: Mee Yon Cho, Sang Yeop Yi, Min seob Eom, Shu Peng Zhang, Hwan Sik Kim, Jong In Lee, Dae Sung Kim; Korean J Pathol. 2006;40(2):128-136.

1,622 View
19 Download

Abstract PDF: BACKGROUND
The expressions of thymidylate synthase (TS), E2F-1, pRb, and p53 are correlated with DNA synthesis. The significance of their expressions is still controversial for predicting the outcome of 5-fluorouracil (5-FU) therapy in the patients with advanced gastric carcinoma. Furthermore, their prognostic value in the metastatic lesions of gastric carcinoma has not yet been confirmed.
METHODS
To ascertain their prognostic value, we immunohistochemically analyzed the expressions of TS, E2F-1, pRb, and p53 in the primary tumors and the related metastatic lymph nodes, and we then compared the survival between the high and low expression group of each protein. Ninety four patients with advanced gastric carcinoma who were treated by complete resection and adjuvant 5-FU chemotherapy were analyzed.
RESULTS
The TS expression in primary tumors was significantly correlated with that of E2F-1. The expression of these genes showed no significant difference between the primary tumors and the metastatic lymph nodes except for E2F-1, which was significantly higher in the lymph node metastasis than in the primary tumors. After complete resection and 5-FU-based adjuvant chemotherapy, patients with a high TS expression in the primary tumors showed a longer survival than those patients having primary tumors with a low TS expression (p=0.0392).
CONCLUSION
A high TS expression in the primary tumors may be related to a better outcome for advanced gastric cancer patients who were treated with 5-FU chemotherapy after curative resection.

Case Report

Fetal Rhabdomyomatous Nephroblastoma: A case report.: Nam Hoon Kim, Chan Pil Park, Eun Kyung Hong, Poong Man Jung, Moon Hyang Park; Korean J Pathol. 1995;29(1):96-102.

1,784 View
46 Download

Abstract PDF: A fetal rhabdomyomatous nephroblastoma is considered to be a predominantly monophasic mesenchymal variant of Wilms' tumor, which acts less aggressively than a conventional Wilms' tumor despite its much larger size. Bilaterality of this tumor in a nine month-old girl, however, may negatively affect the overall prognosis. A radical nephrectomy for bulky masses in the left kidney and a partial nephrectomy for right kidney with five small tumor masses was performed at the same time. Two small tumor masses in the upper part of right kidney were left behind because of preserving minimal renal functional capacity. Pathological study revealed a mixed type of nephroblastoma which was composed predominantly of mesenchymal components with fetal rhabdomyomatous differentiation. After post-operative chemotherapy with vincristine, actinomycin D and adriamycin, and radiotherapy(2,130 rad), residual tumor masses became a single tumor 5 cm in diameter and well demarcated, which was resected at 15 months after first operation when the size and renal function of remained right kidney was appropriate to resect out the residual tumor. The tumor resected out at second operation was entirely composed of scattered differentiated fetal skeletal muscle cells in the fibrovascular tissue. Only a few entrapped epithelial components were seen but no blastemal cornponents were present. Follow up abdominal CT and ultrasonographic examinations revealed no evidence of tumor recurrence. The girl has developed normally without disease.

Original Article

Immunohistochemical Study of the Multidrug Resistant(MDR) Gene Expression in Gastric Carcinoma.: Jung Hee Han, Byung Gon Park, Mi Sook Roh, Sook Hee Hong; Korean J Pathol. 1994;28(1):38-48.

1,517 View
16 Download

Abstract PDF: We performed immunohistochemical stain of p-glycoprotein using JSB-1 monoclonal antibody to study multidrug resistant(MDR) gene expression in 137 gastric tumor tissues obtained from 87gastric carcinoma patients. The incidence of p-glycoprotein expression was 60 of 87 cases(69%) and it was not correlated with age, sex, depth of tumor invasion, and lymph node metastasis, but was correlated with histologic type of gastric adenocarcinoma. The distribution of p-glycoprotein positive cells in the tumor tissue was diffuse in 34 cases(73.9%) and focal in 12 cases(26.1%), and the dominant staining patterns of p-glycoprotein in the tumor cells were cytoplasmic and golgi staining in 20 cases(43.5%) and 19 cases(41.3%), respectively, and 7 cases(15.2%) showed fine granules in the cytoplasm. The incidence of p-glyco-protein expression in the tumor tissue was higher in A and AB blood type patients who have A antigen than in 0 and B blood type patients. Cytoplasmic staining pattern was dominant in O and B blood types and golgi staining in A and AB blood type patients. Among 27 patients 'who received chemotherapy, partial remission was noted in 9 of 11 p-glyco-protein negative patients(81.8%) and no remission or progression of the tumor was seen in 9 of 16 p-glycoprotein positive patient(56.3%). The p-glycoprotein expression in gastric carcinoma had no direct correlation with known several prognostic factors of the gastric tumor except for histologic type, and it is supposed that p-glycoprotein detection in gastric tumor tissue by immunohisto-chemical stain is a good method for predicting the response of chemotherapy, especially in p-gly-coprotein negative cases.

Case Report

Juvenile Granulosa Cell Tumor of the Ovary: Report of a Case of Malignant Form with Unusual Pleomorphism.: Chong Jai Kim, Jin Suk Suh, Sung Hye Park, Je G Chi; Korean J Pathol. 1990;24(3):316-320.

1,815 View
22 Download

Abstract PDF: A case of Juvenile Granulosa Cell Tumor (JGCT) of the ovary with unusual pleomorphic histologic and malignant biologic behaviour is described. The tumor occurred in a 10-year-old girl and was associated with clinical features of isosexual pseudoprecosity and a marked elevation of serum estradiol. The mass manifested initially in the right ovary and subsequently involved the contralateral ovary. A multi-organ metastasis developed during a 6-month-interval despite chemotherapy. She received two operations at 6-month interval, and tissues were obtained from the tumor mass. A marked histologic difference was observed between these two samples. The second biopsy showed profound cellular pleomorphism with numerous multinucleated tumor giant cell formation and hyaline bodies. The differential diagnosis from germ cell tumor and the possible factors for the pleomorphism are discussed.

First
Prev
Page of 1
Next
Last

Search